|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Ambion Inc., of Austin, Texas, was awarded by the National Institute General Medical Sciences, a division of the National Institutes of Health in Bethesda, Md., a $1.6 million Phase II Small Business Innovation Research grant to develop RNA amplification technologies. Ambion said it would use the funds as part of a comprehensive study of RNA amplification.
Amgen Inc., of Thousand Oaks, Calif., filed with the FDA a supplemental biologics license application for its Enbrel (etanercept) manufacturing facility in Rhode Island and for related fill-and-finish operations. Amgen said its goal of gaining approval for the facility would allow it to increase the supply of ...